| NCT06652633 | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies | RECRUITING | PHASE3 | 2024-09-09 | 2039-07 | 2039-07 |
| NCT06043739 | Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects | COMPLETED | PHASE1 | 2023-09-22 | 2023-11-12 | 2023-10-27 |
| NCT05856448 | A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-06-28 | 2026-03 | 2025-10 |
| NCT05695950 | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-02-27 | 2026-04 | 2025-10 |
| NCT05479058 | A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission | TERMINATED | PHASE3 | 2022-07-26 | 2023-10-09 | 2023-10-09 |
| NCT05335447 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 | COMPLETED | PHASE1 | 2022-04-19 | 2022-06-03 | 2022-06-03 |
| NCT06561425 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma | RECRUITING | PHASE1, PHASE2 | 2022-03-09 | 2029-07-01 | 2029-07-01 |
| NCT05272683 | Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects | COMPLETED | PHASE1 | 2022-02-28 | 2022-04-22 | 2022-04-01 |
| NCT05030857 | Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects | COMPLETED | PHASE1 | 2021-09-08 | 2021-11-13 | 2021-11-13 |
| NCT04976270 | A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects | COMPLETED | PHASE1 | 2021-07-20 | 2022-01-14 | 2022-01-14 |
| NCT04971746 | Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects | COMPLETED | PHASE1 | 2021-07-19 | 2022-05-09 | 2022-05-09 |
| NCT04907149 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 | COMPLETED | PHASE1 | 2021-06-07 | 2021-07-12 | 2021-07-12 |
| NCT04856358 | A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects | COMPLETED | PHASE1 | 2021-04-27 | 2021-11-08 | 2021-11-08 |
| NCT04700280 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) | TERMINATED | PHASE2 | 2021-01-28 | 2021-12-27 | 2021-10-28 |
| NCT04736927 | Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects | COMPLETED | PHASE1 | 2021-01-15 | 2021-02-25 | 2021-02-25 |
| NCT04704739 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 | COMPLETED | PHASE1 | 2021-01-13 | 2021-03-10 | 2021-03-02 |
| NCT04720183 | Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects | COMPLETED | PHASE1 | 2021-01-11 | 2021-04-23 | 2021-04-21 |
| NCT04708184 | A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970 | COMPLETED | PHASE1 | 2021-01-11 | 2021-02-25 | 2021-02-25 |
| NCT04700267 | A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus | TERMINATED | PHASE1 | 2020-12-28 | 2021-10-06 | 2021-10-06 |
| NCT04578548 | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | TERMINATED | PHASE2 | 2020-11-10 | 2023-04-04 | 2022-12-14 |
| NCT04653467 | A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects | COMPLETED | PHASE1 | 2020-11-06 | 2022-01-10 | 2022-01-10 |
| NCT04594928 | A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE1 | 2020-10-19 | 2021-05-04 | 2021-05-04 |
| NCT04577781 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate | COMPLETED | PHASE2 | 2020-10-12 | 2021-04-07 | 2021-03-26 |
| NCT04577794 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis | COMPLETED | PHASE2 | 2020-10-05 | 2021-05-31 | 2021-05-17 |
| NCT04575818 | A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059 | TERMINATED | PHASE1 | 2020-09-16 | 2021-04-08 | 2021-04-08 |
| NCT04532567 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects | COMPLETED | PHASE1 | 2020-08-18 | 2020-12-10 | 2020-12-10 |
| NCT04137341 | A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines | COMPLETED | PHASE1 | 2019-10-09 | 2019-12-13 | 2019-12-13 |
| NCT04097938 | A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 | COMPLETED | PHASE1 | 2019-09-18 | 2020-07-06 | 2020-03-04 |
| NCT04136327 | A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection | COMPLETED | PHASE1 | 2019-09-13 | 2019-10-21 | 2019-10-21 |
| NCT04106297 | A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970 | COMPLETED | PHASE1 | 2019-09-10 | 2021-03-05 | 2021-03-05 |
| NCT03976648 | A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis | TERMINATED | PHASE2 | 2019-07-18 | 2021-04-13 | 2021-04-13 |
| NCT03926195 | Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis | COMPLETED | PHASE2 | 2019-05-28 | 2023-05-10 | 2020-08-14 |
| NCT03899909 | A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects | COMPLETED | PHASE1 | 2019-03-29 | 2019-06-03 | 2019-06-03 |
| NCT03864627 | A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis | TERMINATED | PHASE2 | 2019-03-25 | 2020-02-27 | 2020-02-27 |
| NCT03800472 | A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases | COMPLETED | PHASE1 | 2019-01-15 | 2020-03-10 | 2020-03-10 |
| NCT03798366 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis | COMPLETED | PHASE2 | 2019-01-14 | 2020-06-22 | 2020-05-21 |
| NCT03711162 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | TERMINATED | PHASE3 | 2018-11-28 | 2021-03-30 | 2021-03-30 |
| NCT03787186 | A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection | COMPLETED | PHASE1 | 2018-11-09 | 2019-01-17 | 2019-01-17 |
| NCT03733444 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | TERMINATED | PHASE3 | 2018-11-05 | 2021-03-30 | 2021-03-30 |
| NCT03725852 | A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | PHASE2 | 2018-09-27 | 2020-08-14 | 2020-07-21 |
| NCT03595618 | A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis | COMPLETED | PHASE2 | 2018-08-14 | 2020-07-14 | 2020-07-14 |
| NCT03689829 | A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis | TERMINATED | PHASE1 | 2018-08-13 | 2020-03-02 | 2020-03-02 |
| NCT03540524 | A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. | COMPLETED | PHASE1 | 2018-05-31 | 2019-03-11 | 2019-03-11 |
| NCT03568071 | A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis | TERMINATED | PHASE2 | 2018-04-26 | 2020-03-03 | 2020-03-03 |
| NCT03515382 | A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers | COMPLETED | PHASE1 | 2018-03-16 | 2018-06-01 | 2018-06-01 |
| NCT03589313 | Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis. | COMPLETED | PHASE1 | 2018-02-12 | 2018-03-26 | 2018-03-26 |
| NCT03474042 | GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2017-11-29 | 2018-04-10 | 2018-04-10 |
| NCT03320876 | An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. | TERMINATED | PHASE2 | 2017-07-26 | 2021-06-30 | 2021-06-30 |
| NCT03201445 | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease | TERMINATED | PHASE2 | 2017-07-11 | 2023-10-24 | 2020-11-20 |
| NCT03450720 | Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis | COMPLETED | PHASE1 | 2017-06-28 | 2017-08-16 | 2017-08-16 |
| NCT03311009 | A Study With GLPG1972 in Osteoarthritis Subjects | COMPLETED | PHASE1 | 2017-05-15 | 2017-10-25 | 2017-10-25 |
| NCT03143712 | Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet | COMPLETED | PHASE1 | 2017-04-18 | 2017-06-14 | 2017-06-14 |
| NCT03143725 | Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution | COMPLETED | PHASE1 | 2017-04-14 | 2017-06-06 | 2017-06-06 |
| NCT03128606 | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. | COMPLETED | PHASE1 | 2017-03-28 | 2018-02-20 | 2018-02-20 |
| NCT03119649 | A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2017-03-18 | 2017-10-19 | 2017-10-19 |
| NCT02914600 | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease | TERMINATED | PHASE3 | 2017-03-17 | 2023-08-01 | 2023-08-01 |
| NCT03101670 | A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis | COMPLETED | PHASE2 | 2017-03-09 | 2018-03-12 | 2018-03-12 |
| NCT03117270 | A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis | COMPLETED | PHASE2 | 2017-03-07 | 2018-07-02 | 2018-07-02 |
| NCT03045523 | A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2017-01 | 2017-08-11 | 2017-08-11 |
| NCT03410979 | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects | COMPLETED | PHASE1 | 2016-11-25 | 2017-08-15 | 2017-08-15 |
| NCT03214614 | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects | COMPLETED | PHASE1 | 2016-11-14 | 2017-08-25 | 2017-08-25 |
| NCT02914561 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 | 2016-10-31 | 2022-11-11 | 2022-11-11 |
| NCT03102567 | This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects | COMPLETED | PHASE1 | 2016-10-18 | 2017-02-13 | 2017-02-13 |
| NCT02851485 | Bioavailability Study With GLPG1972 | COMPLETED | PHASE1 | 2016-07 | 2016-08 | 2016-07 |
| NCT02788721 | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects | COMPLETED | PHASE1 | 2016-04-14 | 2017-04-27 | 2017-04-27 |
| NCT02739009 | First in Human of Single and Multiple Doses of MOR106 | COMPLETED | PHASE1 | 2016-04 | 2017-08-01 | 2017-08-01 |
| NCT02738801 | Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | PHASE2 | 2016-03 | 2017-05-02 | 2017-05-02 |
| NCT02707562 | Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) | COMPLETED | PHASE2 | 2016-02 | 2016-11 | 2016-11 |
| NCT02690519 | Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) | COMPLETED | PHASE2 | 2016-01 | 2016-09 | 2016-08 |
| NCT02662452 | First-in-Human Single and Multiple Dose of GLPG2222 | COMPLETED | PHASE1 | 2016-01 | 2016-05 | 2016-04 |
| NCT02612246 | First-in-Human Single and Multiple Dose of GLPG1972 | COMPLETED | PHASE1 | 2015-11 | 2016-07 | 2016-04 |
| NCT02623296 | A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects | COMPLETED | PHASE1 | 2015-10 | 2016-02 | 2016-02 |
| NCT02562859 | Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food | COMPLETED | PHASE1 | 2015-09 | 2015-10 | 2015-10 |
| NCT02562950 | A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects | COMPLETED | PHASE1 | 2015-09 | 2015-10 | 2015-10 |
| NCT02337608 | Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis | COMPLETED | PHASE2 | 2014-12 | 2015-11 | 2015-09 |
| NCT02325037 | First-in-Human Single and Multiple Dose of GLPG1837 | COMPLETED | PHASE1 | 2014-12 | 2015-09 | 2015-09 |
| NCT02179502 | First-in-Human Single and Multiple Dose of GLPG1690 | COMPLETED | PHASE1 | 2014-06 | 2014-12 | 2014-11 |
| NCT02162355 | Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects | COMPLETED | PHASE1 | 2014-06 | 2014-09 | 2014-09 |
| NCT02143856 | Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food | COMPLETED | PHASE1 | 2014-05 | 2014-07 | 2014-07 |
| NCT02084199 | Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects | COMPLETED | PHASE1 | 2014-03 | 2014-07 | 2014-07 |
| NCT02065700 | Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants | COMPLETED | PHASE2 | 2014-02-25 | 2023-01-19 | 2023-01-19 |
| NCT02048618 | Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease | COMPLETED | PHASE2 | 2014-02 | 2016-02 | 2015-11 |
| NCT01894516 | Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2) | COMPLETED | PHASE2 | 2013-10-08 | 2015-05-29 | 2015-03-05 |
| NCT01888874 | Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) | COMPLETED | PHASE2 | 2013-07-17 | 2015-05-14 | 2015-02-18 |
| NCT01915667 | Oral Bioavailability of Two Solid Formulations of GLPG0634 | COMPLETED | PHASE1 | 2013-07 | 2013-09 | 2013-09 |
| NCT01887106 | First-in-Human Single and Multiple Dose of GLPG1205 | COMPLETED | PHASE1 | 2013-06 | 2013-10 | 2013-09 |
| NCT01829321 | Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis | COMPLETED | PHASE2 | 2013-04 | 2014-04 | 2014-04 |
| NCT01820806 | Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects | COMPLETED | PHASE1 | 2013-03 | 2013-04 | 2013-04 |
| NCT01798979 | A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects | COMPLETED | PHASE1 | 2013-02 | 2013-04 | 2013-04 |
| NCT01721980 | Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects | COMPLETED | PHASE1 | 2012-10 | 2013-02 | 2013-02 |
| NCT01665924 | Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects | COMPLETED | PHASE1 | 2012-07 | 2012-10 | 2012-09 |
| NCT01668641 | Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients | COMPLETED | PHASE2 | 2012-05 | 2012-10 | 2012-09 |
| NCT01580644 | Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers | COMPLETED | PHASE1 | 2012-01 | 2012-03 | 2012-03 |
| NCT01538420 | GLPG0492 Pharmacodynamics | COMPLETED | PHASE1 | 2012-01 | 2012-04 | 2012-03 |
| NCT01496937 | First-in-Human Exploratory Single Ascending Dose of GLPG0974 | COMPLETED | PHASE1 | 2011-12 | 2012-02 | 2012-01 |
| NCT01419990 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects | COMPLETED | PHASE1 | 2011-08 | 2011-10 | 2011-10 |
| NCT01397370 | Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects | COMPLETED | PHASE1 | 2011-07 | 2011-12 | 2011-12 |
| NCT01384422 | Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients | COMPLETED | PHASE2 | 2011-06 | 2011-11 | 2011-11 |
| NCT01336244 | GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study | COMPLETED | PHASE1 | 2011-04 | 2011-09 | 2011-08 |
| NCT01313598 | GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors | COMPLETED | PHASE1 | 2011-03 | 2013-06 | 2013-05 |
| NCT01278095 | Oral Bioavailability of GLPG0555 in Different Solid Formulations | COMPLETED | PHASE1 | 2011-01 | 2011-03 | 2011-02 |
| NCT01278108 | First-in-Human Single Ascending and Multiple Dose of GLPG0778 | COMPLETED | PHASE1 | 2010-12 | 2011-05 | 2011-02 |
| NCT01322451 | Oral Bioavailability of Two Solid Formulations of GLPG0259. | COMPLETED | PHASE1 | 2010-11 | 2011-01 | 2010-12 |
| NCT01211249 | GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis | COMPLETED | PHASE2 | 2010-10 | 2011-04 | 2011-04 |
| NCT01208753 | Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects | COMPLETED | PHASE1 | 2010-09 | 2011-02 | 2010-11 |
| NCT01179581 | First-in-Human Single Ascending and Multiple Dose of GLPG0634 | COMPLETED | PHASE1 | 2010-08 | 2011-03 | 2011-03 |
| NCT01130818 | First-in-Human Single Ascending Dose of GLPG0492 | COMPLETED | PHASE1 | 2010-05 | 2010-09 | 2010-08 |
| NCT01039103 | Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) | TERMINATED | PHASE2 | 2009-12 | 2011-11 | 2011-11 |
| NCT01023321 | First-in-Human Single Ascending and Multiple Dose of GLPG0555 | COMPLETED | PHASE1 | 2009-12 | 2010-05 | 2010-04 |
| NCT01024517 | GLPG0259 Solid Formulation Bioavailability and Food Effect | COMPLETED | PHASE1 | 2009-11 | 2010-02 | 2009-12 |
| NCT00989703 | GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects | COMPLETED | PHASE1 | 2009-09 | 2010-01 | 2009-11 |
| NCT00928343 | First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187 | COMPLETED | PHASE1 | 2009-06 | 2009-12 | 2009-11 |
| NCT00905138 | First-in-Human Single Ascending and Multiple Dose of GLPG0259 | COMPLETED | PHASE1 | 2009-03 | 2009-06 | 2009-06 |